EC
COLL icon

EntryPoint Capital’s Collegium Pharmaceutical COLL Stock Holding History

EntryPoint Capital’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-6,386
Closed -$247K – 766
2024
Q3 		$247K Buy
6,386
+3,711
+139% +$132K 0.14% 345
2024
Q2 		$86.1K Buy
2,675
+435
+19% +$15.1K 0.13% 372
2024
Q1 		$87K Sell
2,240
-974
-30% -$34.1K 0.08% 499
2023
Q4 		$98.9K Buy
+3,214
New +$80.5K 0.09% 386

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

EntryPoint Capital's COLL Position: Q4 2024 in Review

EntryPoint Capital sold out of Collegium Pharmaceutical (COLL) in Q4 2024, closing a stake of 6,386 shares — an estimated $247K sold.

EntryPoint Capital first reported a position in COLL in Q4 2023 and held it in 4 quarters. The position peaked at $247K in Q3 2024. 238 funds tracked by Wall St. Rank hold COLL as of Q4 2024.

  • EntryPoint Capital reported no remaining Collegium Pharmaceutical position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 6,386 Collegium Pharmaceutical shares in Q4 2024, an estimated $247K.
  • EntryPoint Capital first reported a position in Collegium Pharmaceutical in Q4 2023 and held it in 4 quarters.
  • EntryPoint Capital's Collegium Pharmaceutical position peaked at $247K in Q3 2024.
  • 238 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.